Justin F. Gainor, MD, of Massachusetts General Hospital, discusses updated findings from the ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in patients with advanced RET fusion–positive non–small cell lung cancer (Abstract 9008).
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, discusses study findings on the second-line use of lurbinectedin in patients with both resistant and sensitive small cell lung cancer (Abstract 8506).
Richard Pazdur, MD, Director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence and Acting Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, discusses the launch of Project Facilitate, a new pilot program to assist oncology health-care professionals in requesting access to unapproved therapies for patients with cancer.
Contact Information for Project Facilitate
Health-Care Professionals
Patients and Their Families
Rowan T. Chlebowski, MD, PhD, of the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, discusses study findings from nearly 2 decades of data, which showed a 21% reduction in deaths from breast cancer among postmenopausal women who adhered to a low-fat diet (Abstract 520).
François-Xavier Mahon, MD, PhD, of the Université Bordeaux and Institut Bergonie, discusses results of the ENESTop study, which demonstrated the long-term durability and safety of treatment-free remission in chronic-phase CML after second-line nilotinib (Abstract 7005).
Hope S. Rugo, MD, of the University of California, San Francisco, and Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, discuss ongoing trials of immunotherapy for early triple-negative breast cancer; immunotherapy in other disease subtypes such as estrogen receptor–positive and HER2-positive; and checkpoint inhibition in PD-L1–negative disease.
